Incretins: What is known, new and controversial in 2013?

Diabetes and Metabolism

Volumn 39, Issue 2, 2013, Pages 89-93

  Burcelin, R ^a,b,c   Thorens, B ^d  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Chairman of the European Club for the Study of GLP 1   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Autonomic nervous system; DPP4; GIP; Heart; Incretins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; CARBOHYDRATE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; SULFONYLUREA;

ARTICLE; BARIATRIC SURGERY; BRAIN; COGNITION; DRUG USE; HEART; HEART MUSCLE CELL; HUMAN; INSULIN RELEASE; INSULIN TREATMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; STOMACH EMPTYING;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; LIPIDS; MALE;

EID: 84875926250     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.02.005     Document Type: Article

References (28)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
2. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab 2010, 36(Suppl. 3):S54-S58.
3. Holst J.J., Christensen M., Lund A., de Heer J., Svendsen B., Kielgast U., et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011, 13(Suppl. 1):89-94.
4. Cabou C.B.R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2012, 8:418-431.
5. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
6. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012, 26:871-882.
7. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011, 27:547-558.
8. Cariou B. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. Diabetes Metab 2012, 38:298-308.
9. Burgmaier M., Heinrich C., Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. Diabetic Med 2012, 30(3):289-299.
10. Scheen A.J. Cardiovascular effects of gliptins. Nat Rev Cancer 2012, 13:73-84.
11. Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380:475-483.
12. Laviola L., Leonardini A., Melchiorre M., Orlando M.R., Peschechera A., Bortone A., et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology 2012, 153(12):5770-5781.
13. Giannocco G., Oliveira K.C., Crajoinas R.O., Venturini G., Salles T.A., Fonseca-Alaniz M.H., et al. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol 2012, 698(1-3):74-86.
14. Porter D., Faivre E., Flatt P.R., Holscher C., Gault V.A. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides 2012, 35:1-8.
15. Llewellyn-Smith I.J., Reimann F., Gribble F.M., Trapp S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 2011, 180:111-121.
16. Falken Y., Hellstrom P.M., Holst J.J., Naslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011, 96:2227-2235.
17. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab 2009, 35(6 Pt 2):513-517.
18. Duca F.A., Swartz T.D., Sakar Y., Covasa M. Increased oral detection, but decreased intestinal signaling for fats in mice lacking gut microbiota. PLoS One 2012, 7:e39748.
19. Hansen E.N., Tamboli R.A., Isbell J.M., Saliba J., Dunn J.P., Marks-Shulman P.A., et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol 2011, 300:G795-G802.
20. de Heide L.J., Glaudemans A.W., Oomen P.H., Apers J.A., Totte E.R., van Beek A.P. Functional imaging in hyperinsulinemic hypoglycemia after gastric bypass surgery for morbid obesity. J Clin Endocrinol Metab 2012, 97:E963-E967.
21. Rabiee A., Magruder J.T., Salas-Carrillo R., Carlson O., Egan J.M., Askin F.B., et al. Hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: unraveling the role of gut hormonal and pancreatic endocrine dysfunction. J Surg Res 2011, 167:199-205.
22. Pournaras D.J., Le Roux C.W. The effect of bariatric surgery on gut hormones that alter appetite. Diabetes Metab 2009, 35(6 Pt 2):508-512.
23. Parker H.E., Wallis K., le Roux C.W., Wong K.Y., Reimann F., Gribble F.M. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012, 165:414-423.
24. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
25. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96:14843-14847.
26. Lolmede K., Duffaut C., Zakaroff-Girard A., Bouloumie A. Immune cells in adipose tissue: key players in metabolic disorders. Diabetes Metab 2011, 37:283-290.
27. Gault V.A., O'Harte F.P., Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 2003, 37:253-263.
28. Waget A., Cabou C., Masseboeuf M., Cattan P., Armanet M., Karaca M., et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011, 152:3018-3029.